Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G

被引：2
|
作者：
Sugimoto, Naotoshi
Sakai, Daisuke
Tamura, Takao
Hara, Hiroki
Nishina, Tomohiro
Esaki, Taito
Okuda, Hiroyuki
Denda, Tadamichi
Tsuda, Masahiro
Satoh, Taroh
Makiyama, Akitaka
Yamazaki, Kentaro
Kuramochi, Hidekazu
Hosokawa, Ayumu
Tsuda, Takashi
Taniguchi, Hiroya
Kishimoto, Junji
Boku, Narikazu
Hyodo, Ichinosuke
Muro, Kei
机构：
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Gastrointestinal Oncol, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[3] Kinki Univ, Osaka, Japan
[4] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan
[5] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[6] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Fukuoka, Japan
[7] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[8] Chiba Canc Ctr, Div Gastroenterol, Chiba, Japan
[9] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan
[10] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan
[11] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[12] Tokyo Womens Med Univ, Yachiyo Med Ctr, Yachiyoshi, Chiba, Japan
[13] Toyama Univ, Dept Gastroenterol & Hematol, Fac Med, Toyama, Japan
[14] St Marianna Univ Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan
[15] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[16] Kyushu Univ, Fukuoka, Fukuoka, Japan
[17] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan
[18] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan
[19] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.661
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and oxaliplatin (L-OHP) chemotherapy: WJOG6510G
    Sakai, Daisuke
    Taniguchi, Hiroya
    Tamura, Takao
    Sugimoto, Naotoshi
    Esaki, Taito
    Okuda, Hiroyuki
    Matsumoto, Toshihiko
    Yamazaki, Kentaro
    Denda, Tadamichi
    Yamaguchi, Kensei
    Tsuda, Takashi
    Hosokawa, Ayumu
    Makiyama, Akilaka
    Toblmatsu, Kazutoshi
    Goda, Fuminori
    Otsu, Satoshi
    Kishimoto, Junil
    Boku, Narikazu
    Nakamura, Shinichiro
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] CPT-11/5-fluorouracil(5-FU)/leucchorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) plus cetuximab (Cmab) in unselectecl advanced colorectal cancer (ACC) patients.
    Garufi, C.
    Torsello, A.
    Campanella, C.
    Ettorre, G. M.
    Vennarecci, G.
    Melucci, E.
    Zeuli, M.
    Sperduti, I.
    Gelibter, A.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer.
    Funakoshi, A
    Okusaka, T
    Ishii, H
    Sawaki, A
    Ohkawa, S
    Ishikawa, O
    Saitoh, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 338S - 338S
  • [4] Phase II study of metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with refractory metastatic colorectal cancer (MCRC).
    Moiseyenko, V.
    Chubenko, V.
    Protsenko, S.
    Mikhalichenko, T.
    Moiseyenko, F.
    Brezhnev, N.
    Moiseyenko, A.
    Kornilov, A.
    Zueva, E.
    Gorchakova, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Induction of resectability of colorectal liver metastases (CLM) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) (POCHER trial)
    Garufi, C.
    Torsello, A.
    Tumolo, S.
    Mottolese, M.
    Melucci, E.
    Campanella, C.
    Zeuli, M.
    Sperduti, I.
    Ettorre, G. M.
    Cognetti, F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 348 - 348
  • [6] WJOG6510G: Randomized phase II of Pmab plus IRI vs Cmab plus IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP
    Hara, Hiroki
    Sakai, Daisuke
    Takano, Toshimi
    Shinozaki, Katsunori
    Goto, Masahiro
    Taniguchi, Hiroya
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    ANNALS OF ONCOLOGY, 2017, 28 : 74 - 74
  • [7] CETUXIMAB (CMAB) PLUS CPT-11/5-FLUOROURACIL (5-FU)/LEUCOVORIN(FA)/OXALIPLATIN (L-OHP) (CPT-11-FFL) IN UNRESECTABLE COLORECTAL LIVER METASTASES (CLM): POCHER TRIAL TOXICITY RESULTS
    Torsello, A.
    Garufi, C.
    Tumolo, S.
    Mottolese, M.
    Campanella, C.
    Zeuli, M.
    Sperduti, I
    Pizzi, G.
    Ettorre, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 62 - 63
  • [8] POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM)
    Garufi, C.
    Torsello, A.
    Tumolo, S.
    Mottolese, M.
    Campanella, C.
    Zeuli, M.
    Lo Re, G.
    Sperduti, I.
    Pizzi, G.
    Ettorre, G. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial
    Souglakos, J
    Syrigos, K
    Potamianou, A
    Polyzos, A
    Boukovinas, I
    Androulakis, N
    Kouroussis, C
    Vardakis, N
    Christophilakis, C
    Kotsakis, A
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2004, 15 (08) : 1204 - 1209
  • [10] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
12345